All Outputs (11)

Diagnosis and investigation of suspected haemophagocytic lymphohistiocytosis in adults: 2023 Hyperinflammation and HLH Across Speciality Collaboration (HiHASC) consensus guideline (2023)
Journal Article
Cox, M. F., Mackenzie, S., Low, R., Brown, M., Sanchez, E., Carr, A., …Manson, J. J. (2024). Diagnosis and investigation of suspected haemophagocytic lymphohistiocytosis in adults: 2023 Hyperinflammation and HLH Across Speciality Collaboration (HiHASC) consensus guideline. The Lancet Rheumatology, 6(1), e51-e62. https://doi.org/10.1016/s2665-9913%2823%2900273-4

Haemophagocytic lymphohistiocytosis (HLH) is a hyperinflammatory syndrome characterised by persistently activated cytotoxic lymphocytes and macrophages, which, if untreated, leads to multiorgan dysfunction and death. HLH should be considered in any a... Read More about Diagnosis and investigation of suspected haemophagocytic lymphohistiocytosis in adults: 2023 Hyperinflammation and HLH Across Speciality Collaboration (HiHASC) consensus guideline.

Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience (2023)
Journal Article
Shotton, R., Broadbent, R., Alchawaf, A., Mohamed, M. B., Gibb, A., Martinez-Calle, N., …Linton, K. (2023). Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience. Blood Advances, https://doi.org/10.1182/bloodadvances.2023011305

Introduction: Bendamustine is among the most effective chemotherapeutics for indolent B-cell non-Hodgkin lymphomas (iNHL), but trial reports of significant toxicity, including opportunistic infections and excess deaths, led to prescriber warnings. We... Read More about Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience.

Death from mantle cell lymphoma limits sequential therapy, particularly after first relapse: Patterns of care and outcomes in a series from Australia and the United Kingdom (2023)
Journal Article
Minson, A., Hamad, N., Di Ciaccio, P., Talaulikar, D., Ku, M., Ratnasingam, S., …Dickinson, M. (2024). Death from mantle cell lymphoma limits sequential therapy, particularly after first relapse: Patterns of care and outcomes in a series from Australia and the United Kingdom. British Journal of Haematology, 204(2), 548-554. https://doi.org/10.1111/bjh.19179

Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma characterised by a heterogeneous clinical course. Patients can often receive sequential treatments, yet these typically yield diminishing periods of disease control, raising questions about... Read More about Death from mantle cell lymphoma limits sequential therapy, particularly after first relapse: Patterns of care and outcomes in a series from Australia and the United Kingdom.

Diagnosis and Management of Mantle Cell Lymphoma: A British Society for Haematology Guideline (2023)
Journal Article
Eyre, T. A., Bishton, M. J., McCulloch, R., O'Reilly, M., Menon, G., Iyengar, S., …Haemato-Oncology Task Force of the British Society for Haematology, H. T. F. O. T. B. S. F. H. (2024). Diagnosis and Management of Mantle Cell Lymphoma: A British Society for Haematology Guideline. British Journal of Haematology, 204(1), 108-126. https://doi.org/10.1111/bjh.19131

High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma (2023)
Journal Article
Lewis, K. L., Jakobsen, L. H., Villa, D., Smedby, K. E., Savage, K. J., Eyre, T. A., …Pophali, P. A. (2023). High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma. Journal of Clinical Oncology, https://doi.org/10.1200/JCO.23.00365

PURPOSE CNS progression or relapse is an uncommon but devastating complication of aggressive B-cell lymphoma. There is no consensus regarding the optimal approach to CNS prophylaxis. This study was designed to determine whether high-dose methotrexate... Read More about High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma.

Incidence and Survival in Patients With Enteropathy-associated T-Cell Lymphoma: Nationwide Registry Studies From England and Denmark (2023)
Journal Article
West, J., Jepsen, P., Card, T. R., Crooks, C. J., & Bishton, M. (2023). Incidence and Survival in Patients With Enteropathy-associated T-Cell Lymphoma: Nationwide Registry Studies From England and Denmark. Gastroenterology, 165(4), 1064-1066.e3. https://doi.org/10.1053/j.gastro.2023.06.003

1-year survival in haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003–2018 (2023)
Journal Article
West, J., Stilwell, P., Liu, H., Ban, L., Bythell, M., Card, T., …Crooks, C. (2023). 1-year survival in haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003–2018. Journal of Hematology and Oncology, 16, Article 56. https://doi.org/10.1186/s13045-023-01434-4

Haemophagocytic lymphohistiocytosis (HLH) is a lethal syndrome of excessive immune activation. We undertook a nationwide study in England of all cases of HLH diagnosed between 2003 and 2018, using linked electronic health data from hospital admission... Read More about 1-year survival in haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003–2018.

Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinaemia: patient outcomes and impact of bendamustine dosing (2023)
Journal Article
Arulogun, S. O., Brian, D., Goradia, H., Cooney, A., Menne, T., Koo, R., …D’Sa, S. P. (2023). Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinaemia: patient outcomes and impact of bendamustine dosing. American Journal of Hematology, 98(5), 750-759. https://doi.org/10.1002/ajh.26895

Bendamustine and rituximab (BR) therapy is commonly used in the treatment of Waldenström Macroglobulinaemia (WM). The impact dose of Bendamustine dose on response and survival outcomes is not well established, and the impact of its use in different t... Read More about Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinaemia: patient outcomes and impact of bendamustine dosing.

Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma Alliance (2023)
Journal Article
Barraclough, A., England, J. T., Villa, D., Wight, J., Hapgood, G., Conn, J., …Hawkes, E. A. (2023). Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma Alliance. Haematologica, 108(9), https://doi.org/10.3324/haematol.2022.281375

Grade (G) 3B follicular lymphoma (FL) is a rare FL subtype which exists on a histological continuum between ‘low-grade’ (Grade 1, 2 and 3A FL) and diffuse large B-cell lymphoma (DLBCL) appearing to share features with each. Clinical characteristics a... Read More about Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma Alliance.

Haematology (2023)
Book Chapter
Richardson, R., & Ellis, R. (2023). Haematology. In General Medicine and Surgery: Medical student revision guide (59-81). (1). Scion Publishing

Review for "Risk of a second cancer and infection in patients with indolent B‐cell lymphoma exposed to first‐line bendamustine plus rituximab: A retrospective analysis of an administrative claims database" (2023)
Other
Dote, S., Inose, R., Goto, R., Kobayashi, Y., & Muraki, Y. (2023). Review for "Risk of a second cancer and infection in patients with indolent B‐cell lymphoma exposed to first‐line bendamustine plus rituximab: A retrospective analysis of an administrative claims database"

Bendamustine has a potent immunosuppressive effect because it causes T-cell lymphopenia, which might lead to a second primary malignancy (SPM) and would increase the risk of infection. Using the Medical Data Vision administrative claims database, we... Read More about Review for "Risk of a second cancer and infection in patients with indolent B‐cell lymphoma exposed to first‐line bendamustine plus rituximab: A retrospective analysis of an administrative claims database".